Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

152.80 -1.95 (-1.26%)

Official Closing Price Updated: 4:15 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts ↗

July 31, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals ↗

July 31, 2025

Neurocrine Biosciences (NBIX) offers strong growth, solid profitability, and fair valuation, making it a top pick for affordable growth investors.

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns ↗

July 30, 2025

Neurocrine Biosciences (NBIX) beat Q2 2025 revenue and EPS estimates but stock fell 8.6% amid investor concerns over guidance. INGREZZA sales grew 17% YoY.

Via Chartmill

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential ↗

July 28, 2025

Neurocrine Biosciences (NBIX) shows strong growth potential with solid fundamentals, high profitability, and a bullish technical breakout pattern in the biotech sector.

Via Chartmill

Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗

July 10, 2025

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Via Investor's Business Daily

Topics Intellectual Property

Analyst Expectations For Neurocrine Biosciences's Future ↗

June 02, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts ↗

July 09, 2025

Via Benzinga

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation ↗

July 09, 2025

NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks in the biotech...

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗

July 04, 2025

NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High profitability, no debt, and a potential breakout add to its appeal.

Via Chartmill

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

June 29, 2025

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

Via MarketBeat

Topics Artificial Intelligence Economy

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stock ↗

June 18, 2025

NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth in the biotech sector.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗

June 12, 2025

NEUROCRINE BIOSCIENCES (NBIX) shows strong growth, profitability, and a bullish technical setup, making it a stock worth watching for growth investors.

Via Chartmill

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation ↗

May 28, 2025

NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential ↗

May 21, 2025

NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities.

Via Chartmill

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target ↗

May 06, 2025

Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.

Via Benzinga

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug ↗

May 06, 2025

The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands.

Via Investor's Business Daily

FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday ↗

May 06, 2025

Via Benzinga

What 19 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

May 06, 2025

Via Benzinga

Neurocrine Biosciences Stock Surges After-Hours On Upbeat Q1, Reaffirmed Ingrezza Outlook — Retail Buzz Soars ↗

May 05, 2025

CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.

Via Stocktwits

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 05, 2025

Via Benzinga

Top movers in Monday's after hours session ↗

May 05, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing. ↗

May 05, 2025

Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...

Via Chartmill

What to Expect from Neurocrine Biosciences's Earnings ↗

May 02, 2025

Via Benzinga

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock ↗

May 01, 2025

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock

Via Chartmill

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗

April 20, 2025

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Via Benzinga

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish ↗

April 15, 2025

Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH.

Via Benzinga

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

April 15, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

All News about Neurocrine Biosciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today